Comparative antiproliferative efects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines

Cancer Biology and Therapy

Volumn 14, Issue 6, 2013, Pages 537-545

  Pierce, Aisling ^a,b   Mcgowan, Patricia M ^a,b   Cotter, Maura ^a,b   Mullooly, Maeve ^a,b   O'Donovan, Norma ^c   Rani, Sweta ^d   O'Driscoll, Lorraine ^d   Crown, John ^a   Dufy, Michael J ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c DUBLIN CITY UNIVERSITY   (Ireland)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Breast cancer; CDK1; Iniparib; Olaparib; PARP inhibitors; Triple negative

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE 1; INIPARIB; MICRORNA 182; NERATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; DRUG EFFICACY; HUMAN; HUMAN CELL; IC 50; TRIPLE NEGATIVE BREAST CANCER;

EID: 84879186647     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.24349     Document Type: Article

References (32)

1. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010; 39:8-24; PMID:20603072; http://dx.doi.org/10.1016/j.molcel. 2010.06.017.
2. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10:293-301; PMID:20200537; http://dx.doi.org/10.1038/nrc2812.
3. Yap TA, Sandhu SK, Carden CP, de Bono JS. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 2011; 61:31-49; PMID:21205831; http://dx.doi.org/10.3322/caac. 20095.
4. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-34; PMID:19553641; http://dx.doi.org/10.1056/ NEJMoa0900212.
5. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376:235-44; PMID:20609467; http://dx.doi.org/10.1016/S0140-6736(10)60892- 6.
6. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376:245-51; PMID:20609468; http://dx.doi.org/10.1016/S0140- 6736(10)60893-8.
7. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, nonrandomised study. Lancet Oncol 2011; 12:852-61; PMID:21862407; http://dx.doi.org/10.1016/S1470-2045(11)70214-5.
8. Ashworth A. Drug resistance caused by reversion mutation. [Review]. Cancer Res 2008; 68:10021-3; PMID:19074863; http://dx.doi.org/10.1158/0008-5472. CAN-08-2287.
9. Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol 2010; 7:508-19; PMID:20700108; http://dx.doi.org/10.1038/nrclinonc.2010.116.
10. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4:814-9; PMID:15510162; http://dx.doi.org/10.1038/ nrc1457.
11. Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, et al. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res 2010; 16:4702-10; PMID:20858840; http://dx.doi.org/10.1158/1078-0432.CCR-10-0939.
12. Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 2012; 118:2787-95; PMID:22614657; http://dx.doi.org/10. 1002/cncr.26576.
13. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364:205-14; PMID:21208101; http://dx.doi.org/10.1056/NEJMoa1011418.
14. O'Shaughnessy JS, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011;29:107.
15. Ossovskaya V, Li L, Broude E, Lim CU, Roninson I, Bradley C, et al. (2009) BSI-201 enhances the activity of multiple classes of cytotoxic agents and irridation in triple negative breast cancer [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22, Denver, CO. Philadelphia: AACR. Abstract nr 5552.
16. Ji J, Lee MP, Kadota M, et al. (2011) Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201 [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; Apr 17-21; Washington, DC. Philadelphia (PA): AACR; 2011. Abstract nr 4527.
17. Maegley KA, Bingham P, Dalvie D, Bergqvist S, Tatlock J, Kania R. (2010) An in vitro mechanistic comparison of clinical PARP inhibitors. PARP 2010. In: Proceedings of the 18th International Conference on ADP-ribose metabolism; Aug 18-21; Zurich, Switzerland. Abstract nr 72.
18. Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011; 17:875-82; PMID:21706030; http://dx.doi.org/10.1038/nm.2377.
19. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011; 41:210-20; PMID:21195000; http://dx.doi.org/10.1016/j.molcel. 2010.12.005.
20. Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012; 18:510-23; PMID:22128301; http://dx.doi.org/10.1158/1078-0432.CCR-11-1973.
21. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADPRibose) polymerase in vitro. Clin Cancer Res 2012; 18:1655-62; PMID:22291137; http://dx.doi.org/10.1158/1078-0432.CCR-11-2890.
22. Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 2012; 134:649-59; PMID:22678161; http://dx.doi.org/10.1007/s10549-012-2106-5.
23. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADPRibose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 2010; 70:7970-80; PMID:20798217; http://dx.doi.org/10.1158/0008-5472.CAN-09-4521.
24. Nowsheen S, Cooper T, Bonner JA, LoBuglio AF, Yang ES. HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res 2012; 72:4796-806; PMID:22987487; http://dx.doi.org/10.1158/0008-5472.CAN-12- 1287.
25. Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, et al. Cross-platform pathwaybased analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat 2012; 135:505-17; PMID:22875744; http://dx.doi.org/10.1007/s10549-012-2188-0.
26. Nowsheen S, Cooper T, Stanley JA, Yang ES. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS One 2012; 7:e46614; PMID:23071597; http://dx.doi.org/10.1371/journal.pone. 0046614.
27. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012; 2:1036-47; PMID:22915752; http://dx.doi.org/10.1158/2159-8290.CD-11-0348.
28. Drew Y, Mulligan EA, Vong W-T, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of poly(ADPribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011; 103:334-46; PMID:21183737; http://dx.doi.org/10.1093/jnci/djq509.
29. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-67; PMID: 21633166; http://dx.doi.org/10.1172/JCI45014.
30. Hughes L, Malone C, Chumsri S, Burger AM, McDonnell S. Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin Exp Metastasis 2008; 25:549-57; PMID:18386134; http://dx.doi.org/10.1007/s10585-008-9169-z.
31. McGowan PM, Mullooly M, Caiazza F, Sukor S, Madden SF, Maguire AA, et al. ADAM-17: a novel therapeutic target for triple negative breast cancer. Ann Oncol 2013; 24:362-; PMID:22967992; http://dx.doi.org/10.1093/annonc/mds279.
32. Rani S, Clynes M, O'Driscoll L. Detection of amplifiable mRNA extracellular to insulin-producing cells: potential for predicting beta cell mass and function. Clin Chem 2007; 53:1936-44; PMID:17717131; http://dx.doi.org/10.1373/clinchem.2007.087973.